Otis
Expected and Observed Case Counts, with Standardized Incidence Ratios, 1995 - 1999

	<u>Exp</u>	<u>Obs</u>	SIR		<u>Exp</u>	<u>Obs</u>	SIR
Bladder, Urinary	0.00		Not	Melanoma of Skin	2.52	•	NO
Male -	0.68	1	NC*	Male -	0.50	0	NC*
Female	0.24	0	NC*	Female	0.36	0	NC*
Total	0.93	1	NC*	Total	0.86	0	NC*
Brain and Other Cent				Multiple Myeloma	• • •		
Male 	0.23	2	NC*	Male	0.14	0	NC*
Female	0.17	1	NC*	Female	0.11	0	NC*
Total	0.41	3	NC*	Total	0.25	0	NC*
<u>Breast</u>	0.00	•	Not	Non-Hodgkin('s) Lyn		•	N.O.*
Male	0.03	0	NC*	Male	0.60	0	NC*
Female	4.18	3	NC*	Female	0.49	1	NC*
Total	4.21	3	NC*	Total	1.08	1	NC*
Cervix Uteri				Oral Cavity and Phar		•	N.O.*
				Male	0.47	0	NC*
Female	0.26	1	NC*	Female	0.20	0	NC*
				Total	0.67	0	NC*
Colon / Rectum				<u>Ovary</u>			
Male -	1.73	2	NC*				
Female	1.53	2	NC*	Female	0.49	1	NC*
Total	3.26	4	NC*	_			
<u>Esophagus</u>				<u>Pancreas</u>		_	
Male	0.26	0	NC*	Male	0.30	0	NC*
Female	0.07	0	NC*	Female	0.28	0	NC*
Total	0.34	0	NC*	Total	0.58	0	NC*
Hodgkin's Disease (H				<u>Prostate</u>		_	4.40
Male	0.12	0	NC*	Male	4.55	5	110
Female	0.09	0	NC*				
Total	0.21	0	NC*	•			
Kidney and Renal Pe		•		<u>Stomach</u>			
Male 	0.44	0	NC*	Male	0.29	0	NC*
Female	0.24	0	NC*	Female	0.17	0	NC*
Total .	0.68	0	NC*	Total	0.46	0	NC*
<u>Larynx</u>	0.05	4	NO*	<u>Testis</u>	0.40	•	NO*
Male	0.25	1	NC*	Male	0.19	0	NC*
Female	0.06	0	NC*				
Total	0.31	1	NC*	- 1 · 1			
<u>Leukemia</u>	0.05	•	NO*	<u>Thyroid</u>	0.44	•	NO*
Male	0.35	0	NC*	Male	0.11	0	NC*
Female	0.25	1	NC*	Female	0.27	0	NC*
Total	0.60	1	NC*	Total	0.38	0	NC*
Liver and Intrahepati		^	NO*	Uteri, Corpus and Ut	erus, NOS		
Male	0.17	0	NC*		0.70	4	NO*
Female	0.06	0	NC*	Female	0.79	1	NC*
Total	0.23	0	NC*	A II A II -			
Lung and Bronchus	0.00	4	NO*	All Sites / Types	44.00	40	20
Male	2.29	1	NC*	Male	14.68	12	82
Female	1.65	3	NC*	Female	12.89	15	116
Total	3.94	4	NC*	Total	27.57	27	98

Obs = observed case count

- + indicates number of observed cases is statistically significantly higher than the expected number of cases
- indicates number of observed cases is statistically significantly lower than the expected number of cases # indicates statistical significance at the $\mathbf{p} \leq 0.05$ level
- ~ indicates statistical significance at the $p \le 0.01$ level, as well as at the $p \le 0.05$ level
- \land indicates statistical significance at the $\mathbf{p} \le 0.001$ level, as well as at the $\mathbf{p} \le 0.05$ and $\mathbf{p} \le 0.01$ levels

Oxford
Expected and Observed Case Counts, with Standardized Incidence Ratios, 1995 - 1999

	<u>Exp</u>	<u>Obs</u>	SIR		<u>Exp</u>	<u>Obs</u>	<u>SIR</u>
Bladder, Urinary				Melanoma of Skin			
Male	7.36	8	109	Male	5.21	6	115
Female	2.87	1	NC*	Female	4.15	3	NC*
Total	10.23	9	88	Total	9.36	9	96
Brain and Other Co	entral Nervous S	<u>System</u>		Multiple Myeloma			
Male	2.42	5	207	Male	1.46	2	NC*
Female	1.99	4	NC*	Female	1.32	2	NC*
Total	4.40	9	205	Total	2.78	4	NC*
<u>Breast</u>				Non-Hodgkin('s) Ly	mphoma		
Male	0.35	1	NC*	Male	6.27	8	128
Female	48.74	48	98	Female	5.67	5	88
Total	49.09	49	100	Total	11.95	13	109
Cervix Uteri				Oral Cavity and Pha	rynx		
				Male	4.89	5	102
Female	2.90	5	172	Female	2.38	2	NC*
				Total	7.27	7	96
Colon / Rectum				<u>Ovary</u>			
Male	18.39	13	71				
Female	17.96	19	106	Female	5.73	7	122
Total	36.35	32	88				
Esophagus				<u>Pancreas</u>			
Male	2.74	2	NC*	Male	3.15	5	159
Female	0.87	1	NC*	Female	3.32	5	151
Total	3.61	3	NC*	Total	6.47	10	155
Hodgkin's Disease	(Hodgkin Lymp	<u>homa)</u>		<u>Prostate</u>			
Male	1.27	1	NC*	Male	46.57	40	86
Female	1.01	0	NC*				
Total	2.28	1	NC*				
Kidney and Renal	<u>Pelvis</u>			Stomach			
Male	4.54	11	242 #+	Male	3.15	1	NC*
Female	2.89	4	NC*	Female	1.95	2	NC*
Total	7.44	15	202 #+	Total	5.10	3	NC*
<u>Larynx</u>				<u>Testis</u>			
Male	2.59	1	NC*	Male	1.98	4	NC*
Female	0.67	1	NC*				
Total	3.26	2	NC*				
<u>Leukemia</u>				<u>Thyroid</u>			
Male	3.66	7	191	Male	1.10	2	NC*

^{* =} **SIR** and statistical significance not calculated when **Obs** < 5

Female	2.94	2	NC*	Female	3.01	1	NC*
Total	6.60	9	136	Total	4.10	3	NC*
Liver and Intrahepa	atic Bile Ducts			Uteri, Corpus and U	terus, NOS		
Male	1.76	0	NC*				
Female	0.74	0	NC*	Female	9.37	6	64
Total	2.50	0	NC*				
Lung and Bronchu	<u>s</u>			All Sites / Types			
Male	23.65	20	85	Male	152.87	153	100
Female	19.66	15	76	Female	150.84	145	96
Total	43.31	35	81	Total	303.71	298	98

Obs = observed case count

- + indicates number of observed cases is statistically significantly higher than the expected number of cases
- indicates number of observed cases is statistically significantly lower than the expected number of cases # indicates statistical significance at the $\mathbf{p} \leq 0.05$ level
- ~ indicates statistical significance at the $p \le 0.01$ level, as well as at the $p \le 0.05$ level
- \land indicates statistical significance at the $p \le 0.001$ level, as well as at the $p \le 0.05$ and $p \le 0.01$ levels

Palmer
Expected and Observed Case Counts, with Standardized Incidence Ratios, 1995 - 1999

	<u>Exp</u>	<u>Obs</u>	<u>SIR</u>		<u>Exp</u>	<u>Obs</u>	<u>SIR</u>
Bladder, Urinary				Melanoma of Skin			
Male	8.45	12	142	Male	5.48	4	NC*
Female	3.52	3	NC*	Female	4.35	4	NC*
Total	11.97	15	125	Total	9.84	8	81
Brain and Other Cer	ntral Nervous S	<u>ystem</u>		Multiple Myeloma			
Male	2.44	2	NC*	Male	1.64	0	NC*
Female	2.08	3	NC*	Female	1.54	1	NC*
Total	4.52	5	111	Total	3.18	1	NC*
<u>Breast</u>				Non-Hodgkin('s) Lyı	<u>mphoma</u>		
Male	0.39	0	NC*	Male	6.66	4	NC*
Female	52.23	44	84	Female	6.49	3	NC*
Total	52.62	44	84	Total	13.16	7	53
Cervix Uteri				Oral Cavity and Pha	<u>rynx</u>		
				Male	5.05	5	99
Female	2.87	7	244	Female	2.65	2	NC*
				Total	7.70	7	91
Colon / Rectum				<u>Ovary</u>			
Male	20.90	21	100				
Female	22.15	17	77	Female	6.07	13	214 #+
Total	43.06	38	88				
Esophagus				<u>Pancreas</u>			
Male	2.94	1	NC*	Male	3.48	4	NC*
Female	1.08	1	NC*	Female	4.06	4	NC*
Total	4.02	2	NC*	Total	7.54	8	106
Hodgkin's Disease	(Hodgkin Lymp	<u>homa)</u>		<u>Prostate</u>			
Male	1.21	0	NC*	Male	51.15	49	96
Female	0.99	1	NC*				

^{* =} SIR and statistical significance not calculated when **Obs** < 5

Total	2.20	1	NC*				
Kidney and Renal P	<u>elvis</u>			Stomach			
Male	4.87	6	123	Male	3.51	5	142
Female	3.24	2	NC*	Female	2.41	4	NC*
Total	8.11	8	99	Total	5.92	9	152
<u>Larynx</u>				<u>Testis</u>			
Male	2.75	8	291 #+	Male	1.84	2	NC*
Female	0.73	2	NC*				
Total	3.47	10	288 ~+				
<u>Leukemia</u>				Thyroid			
Male	3.94	3	NC*	Male	1.06	0	NC*
Female	3.28	6	183	Female	2.89	5	173
Total	7.22	9	125	Total	3.95	5	127
Liver and Intrahepat	tic Bile Ducts			Uteri, Corpus and U	Iterus, NOS		
Male	1.88	5	266				
Female	0.88	2	NC*	Female	10.07	9	89
Total	2.76	7	254 #+				
Lung and Bronchus	<u>i</u>			All Sites / Types			
Male	26.43	35	132	Male	167.46	178	106
Female	22.41	20	89	Female	168.68	158	94
Total	48.84	55	113	Total	336.14	336	100

Obs = observed case count

- + indicates number of observed cases is statistically significantly higher than the expected number of cases
- indicates number of observed cases is statistically significantly lower than the expected number of cases # indicates statistical significance at the $\mathbf{p} \leq 0.05$ level
- ~ indicates statistical significance at the $p \le 0.01$ level, as well as at the $p \le 0.05$ level
- \land indicates statistical significance at the $p \le 0.001$ level, as well as at the $p \le 0.05$ and $p \le 0.01$ levels

Paxton
Expected and Observed Case Counts, with Standardized Incidence Ratios, 1995 - 1999

	<u>Exp</u>	<u>Obs</u>	<u>SIR</u>		<u>Exp</u>	<u>Obs</u>	SIR
Bladder, Urinary				Melanoma of Skin			
Male	3.38	3	NC*	Male	2.23	4	NC*
Female	1.17	0	NC*	Female	1.63	2	NC*
Total	4.55	3	NC*	Total	3.87	6	155
Brain and Other Cer	ntral Nervous S	<u>ystem</u>		Multiple Myeloma			
Male	0.99	0	NC*	Male	0.67	0	NC*
Female	0.78	2	NC*	Female	0.55	1	NC*
Total	1.77	2	NC*	Total	1.23	1	NC*
<u>Breast</u>				Non-Hodgkin('s) Lym	<u>phoma</u>		
Male	0.16	1	NC*	Male	2.67	2	NC*
Female	20.29	20	99	Female	2.30	1	NC*
Total	20.46	21	103	Total	4.97	3	NC*
Cervix Uteri				Oral Cavity and Phar	<u>ynx</u>		
				Male	2.17	0	NC*
Female	1.10	1	NC*	Female	0.99	0	NC*
				Total	3.16	0	NC*

^{* =} **SIR** and statistical significance not calculated when **Obs** < 5

Colon / Rectum				<u>Ovary</u>			
Male	8.44	2	NC*				
Female	7.30	6	82	Female	2.35	1	NC*
Total	15.74	8	51				
Esophagus				<u>Pancreas</u>			
Male	1.26	0	NC*	Male	1.44	2	NC*
Female	0.36	0	NC*	Female	1.37	1	NC*
Total	1.61	0	NC*	Total	2.81	3	NC*
Hodgkin's Disease	(Hodgkin Lymph	<u>noma)</u>		Prostate			
Male	0.44	0	NC*	Male	22.03	21	95
Female	0.35	0	NC*				
Total	0.79	0	NC*				
Kidney and Renal P	<u>elvis</u>			Stomach			
Male	2.04	3	NC*	Male	1.42	1	NC*
Female	1.21	1	NC*	Female	0.78	1	NC*
Total	3.25	4	NC*	Total	2.20	2	NC*
<u>Larynx</u>				<u>Testis</u>			
Male	1.19	1	NC*	Male	0.61	1	NC*
Female	0.29	0	NC*				
Total	1.48	1	NC*				
<u>Leukemia</u>				<u>Thyroid</u>			
Male	1.56	2	NC*	Male	0.42	1	NC*
Female	1.17	0	NC*	Female	1.10	2	NC*
Total	2.73	2	NC*	Total	1.52	3	NC*
Liver and Intrahepa	tic Bile Ducts			Uteri, Corpus and U	Iterus, NOS		
Male	0.79	0	NC*				
Female	0.30	0	NC*	Female	4.01	4	NC*
Total	1.10	0	NC*				
Lung and Bronchus	<u>s</u>			All Sites / Types			
Male	11.05	5	45	Male	69.44	53	76 #-
Female	8.39	6	72	Female	62.08	53	85
Total	19.44	11	57	Total	131.52	106	81 #-

Obs = observed case count

- + indicates number of observed cases is statistically significantly higher than the expected number of cases
- indicates number of observed cases is statistically significantly lower than the expected number of cases # indicates statistical significance at the $\mathbf{p} \leq 0.05$ level
- ~ indicates statistical significance at the $p \le 0.01$ level, as well as at the $p \le 0.05$ level
- \land indicates statistical significance at the $p \leq 0.001$ level, as well as at the $p \leq 0.05$ and $p \leq 0.01$ levels

PeabodyExpected and Observed Case Counts, with Standardized Incidence Ratios, 1995 - 1999

	<u>Exp</u>	<u>Obs</u>	SIR		<u>Exp</u>	<u>Obs</u>	SIR
Bladder, Urinary				Melanoma of Skin			
Male	34.79	40	115	Male	23.15	28	121
Female	13.89	15	108	Female	18.07	14	77
Total	48.68	55	113	Total	41.22	42	102
Brain and Other Ce	entral Nervous S	<u>System</u>		Multiple Myeloma			

^{* =} SIR and statistical significance not calculated when **Obs** < 5

Male	10.32	8	78	Male	6.84	10	146
Female	8.57	5	58	Female	6.29	10	159
Total	18.88	13	69	Total	13.13	20	152
<u>Breast</u>				Non-Hodgkin('s) Ly	mphoma		
Male	1.66	2	NC*	Male	27.82	34	122
Female	220.83	246	111	Female	26.34	33	125
Total	222.48	248	111	Total	54.17	67	124
Cervix Uteri				Oral Cavity and Pha	<u>arynx</u>		
				Male	21.89	23	105
Female	12.08	10	83	Female	10.98	11	100
				Total	32.87	34	103
Colon / Rectum				<u>Ovary</u>			
Male	86.90	100	115				
Female	86.93	93	107	Female	25.60	24	94
Total	173.84	193	111				
Esophagus				<u>Pancreas</u>			
Male	12.70	16	126	Male	14.70	16	109
Female	4.25	1	NC*	Female	16.15	14	87
Total	16.94	17	100	Total	30.85	30	97
Hodgkin's Diseas	se (Hodgkin Lymp	<u>homa)</u>		<u>Prostate</u>			
Male	5.02	8	159	Male	223.34	253	113
Female	3.99	4	NC*				
Total	9.01	12	133				
Kidney and Rena	al Pelvis			Stomach			
Male	20.69	32	155 #+	Male	14.57	9	62
Female	13.47	17	126	Female	9.35	9	96
Total	34.16	49	143 #+	Total	23.92	18	75
<u>Larynx</u>				<u>Testis</u>			
Male	11.99	17	142	Male	7.49	6	80
Female	3.14	3	NC*				
Total	15.13	20	132				
<u>Leukemia</u>				<u>Thyroid</u>			
Male	16.16	13	80	Male	4.55	2	NC*
Female	13.11	16	122	Female	12.11	13	107
Total	29.27	29	99	Total	16.66	15	90
Liver and Intrahe				Uteri, Corpus and L	<u> Iterus, NOS</u>		
Male	8.07	13	161				
Female	3.52	4	NC*	Female	43.12	49	114
Total	11.59	17	147				
Lung and Broncl				All Sites / Types			
Male	112.73	142	126 ~+	Male	712.19	824	116 ^+
Female	93.81	110	117	Female	695.68	759	109 #+
Total	206.54	252	122 ~+	Total	1407.86	1583	112 ^+

Obs = observed case count

 $^{^{*}}$ = SIR and statistical significance not calculated when **Obs** < 5

⁺ indicates number of observed cases is statistically significantly higher than the expected number of cases

⁻ indicates number of observed cases is statistically significantly lower than the expected number of cases

[#] indicates statistical significance at the $\mathbf{p} \leq 0.05$ level

[~] indicates statistical significance at the $p \le 0.01$ level, as well as at the $p \le 0.05$ level

Pelham
Expected and Observed Case Counts, with Standardized Incidence Ratios, 1995 - 1999

	<u>Exp</u>	<u>Obs</u>	SIR		<u>Exp</u>	<u>Obs</u>	SIR
Bladder, Urinary				Melanoma of Skin			
Male	1.07	0	NC*	Male	0.70	1	NC*
Female	0.30	0	NC*	Female	0.49	0	NC*
Total	1.37	0	NC*	Total	1.19	1	NC*
Brain and Other Cent	ral Nervous S	<u>System</u>		Multiple Myeloma			
Male	0.31	0	NC*	Male	0.21	0	NC*
Female	0.23	0	NC*	Female	0.15	0	NC*
Total	0.54	0	NC*	Total	0.36	0	NC*
<u>Breast</u>				Non-Hodgkin('s) Lym	<u>ıphoma</u>		
Male	0.05	0	NC*	Male	0.85	0	NC*
Female	5.83	7	120	Female	0.64	0	NC*
Total	5.88	7	119	Total	1.48	0	NC*
Cervix Uteri				Oral Cavity and Phar	<u>ynx</u>		
				Male	0.68	0	NC*
Female	0.35	0	NC*	Female	0.27	0	NC*
				Total	0.95	0	NC*
Colon / Rectum				<u>Ovary</u>			
Male	2.66	2	NC*				
Female	1.90	2	NC*	Female	0.68	0	NC*
Total	4.56	4	NC*				
<u>Esophagus</u>				<u>Pancreas</u>			
Male	0.39	0	NC*	Male	0.46	0	NC*
Female	0.09	0	NC*	Female	0.36	0	NC*
Total	0.49	0	NC*	Total	0.81	0	NC*
Hodgkin's Disease (H		<u>homa)</u>		<u>Prostate</u>			
Male	0.15	0	NC*	Male	6.88	5	73
Female	0.11	0	NC*				
Total	0.26	0	NC*				
Kidney and Renal Pel				Stomach			
Male	0.63	3	NC*	Male	0.45	0	NC*
Female	0.33	1	NC*	Female	0.20	0	NC*
Total	0.96	4	NC*	Total	0.65	0	NC*
<u>Larynx</u>				<u>Testis</u>			
Male	0.37	0	NC*	Male	0.21	0	NC*
Female	0.08	0	NC*				
Total	0.45	0	NC*				
<u>Leukemia</u>				<u>Thyroid</u>			
Male	0.49	0	NC*	Male	0.14	1	NC*
Female	0.32	0	NC*	Female	0.36	0	NC*
Total	0.80	0	NC*	Total	0.50	1	NC*
Liver and Intrahepation				Uteri, Corpus and Ute	erus, NOS		
Male	0.25	0	NC*				
Female	0.08	0	NC*	Female	1.14	3	NC*
Total	0.33	0	NC*				
Lung and Bronchus				All Sites / Types			
Male	3.43	2	NC*	Male	21.79	18	83
Female	2.31	0	NC*	Female	17.37	14	81

Total 5.74 2 NC* Total 39.16 32 82

Exp = expected case count, based on the Massachusetts average age-specific incidence rates for this cancer

SIR = standardized incidence ratio [(Obs / Exp) X 100]

Obs = observed case count

- + indicates number of observed cases is statistically significantly higher than the expected number of cases
- indicates number of observed cases is statistically significantly lower than the expected number of cases # indicates statistical significance at the $\mathbf{p} \leq 0.05$ level
- ~ indicates statistical significance at the $p \le 0.01$ level, as well as at the $p \le 0.05$ level
- \land indicates statistical significance at the $p \le 0.001$ level, as well as at the $p \le 0.05$ and $p \le 0.01$ levels

Pembroke
Expected and Observed Case Counts, with Standardized Incidence Ratios, 1995 - 1999

	Expedied a	ila Observea v	Jase Counts, with	i Otalidaldized ilicidelice i	Katios, 1333 - 13	999	
	<u>Exp</u>	<u>Obs</u>	<u>SIR</u>		<u>Exp</u>	<u>Obs</u>	SIR
Bladder, Urinary				Melanoma of Skin			
Male	7.71	23	298 ^+	Male	5.99	5	84
Female	2.78	3	NC*	Female	4.54	6	132
Total	10.49	26	248 ^+	Total	10.53	11	104
Brain and Other Ce	ntral Nervous S	<u>System</u>		Multiple Myeloma			
Male	2.84	1	NC*	Male	1.62	3	NC*
Female	2.16	6	278 #+	Female	1.34	3	NC*
Total	5.01	7	140	Total	2.96	6	203
<u>Breast</u>				Non-Hodgkin('s) Lyı	mphoma		
Male	0.39	0	NC*	Male	7.07	11	156
Female	53.59	63	118	Female	5.79	4	NC*
Total	53.99	63	117	Total	12.86	15	117
Cervix Uteri				Oral Cavity and Pha	<u>rynx</u>		
				Male	5.83	4	NC*
Female	3.26	7	215	Female	2.53	2	NC*
				Total	8.36	6	72
Colon / Rectum				<u>Ovary</u>			
Male	19.53	14	72				
Female	17.34	14	81	Female	6.30	9	143
Total	36.86	28	76				
Esophagus				<u>Pancreas</u>			
Male	3.14	5	159	Male	3.45	6	174
Female	0.84	3	NC*	Female	3.21	4	NC*
Total	3.98	8	201	Total	6.66	10	150
Hodgkin's Disease	(Hodgkin Lymp	homa <u>)</u>		<u>Prostate</u>			
Male	1.48	1	NC*	Male	52.06	57	109
Female	1.10	0	NC*				
Total	2.58	1	NC*				
Kidney and Renal P	<u>elvis</u>			<u>Stomach</u>			
Male	5.25	8	152	Male	3.40	5	147
Female	3.03	1	NC*	Female	1.88	1	NC*
Total	8.28	9	109	Total	5.27	6	114
<u>Larynx</u>				<u>Testis</u>			
Male	3.04	1	NC*	Male	2.26	1	NC*
Female	0.73	0	NC*				
Total	3.77	1	NC*				

^{* =} SIR and statistical significance not calculated when **Obs** < 5

<u>Leukemia</u>				<u>Thyroid</u>			
Male	4.08	3	NC*	Male	1.32	1	NC*
Female	3.10	2	NC*	Female	3.40	5	147
Total	7.18	5	70	Total	4.72	6	127
Liver and Intrahe	patic Bile Ducts			Uteri, Corpus and U	Iterus, NOS		
Male	2.03	0	NC*				
Female	0.73	1	NC*	Female	10.33	16	155
Total	2.76	1	NC*				
Lung and Bronch	<u>us</u>			All Sites / Types			
Male	25.95	28	108	Male	169.67	189	111
Female	20.20	28	139	Female	158.98	189	119 #+
Total	46.15	56	121	Total	328.65	378	115 ~+

Obs = observed case count

- + indicates number of observed cases is statistically significantly higher than the expected number of cases
- indicates number of observed cases is statistically significantly lower than the expected number of cases # indicates statistical significance at the $\mathbf{p} \leq 0.05$ level
- ~ indicates statistical significance at the $p \le 0.01$ level, as well as at the $p \le 0.05$ level
- \land indicates statistical significance at the $p \le 0.001$ level, as well as at the $p \le 0.05$ and $p \le 0.01$ levels

Pepperell
Expected and Observed Case Counts, with Standardized Incidence Ratios, 1995 - 1999

	<u>Exp</u>	<u>Obs</u>	SIR		Exp	<u>Obs</u>	SIR
Bladder, Urinary		· 		Melanoma of Skin	 -		
Male	4.56	10	219 #+	Male	3.84	6	156
Female	1.82	2	NC*	Female	3.09	0	NC*
Total	6.38	12	188	Total	6.93	6	87
Brain and Other C	Central Nervous S	<u>ystem</u>		Multiple Myeloma			
Male	1.91	2	NC*	Male	0.98	1	NC*
Female	1.47	1	NC*	Female	0.87	1	NC*
Total	3.38	3	NC*	Total	1.86	2	NC*
<u>Breast</u>				Non-Hodgkin('s) Lym			
Male	0.24	0	NC*	Male	4.53	2	NC*
Female	35.46	34	96	Female	3.84	8	208
Total	35.70	34	95	Total	8.36	10	120
Cervix Uteri				Oral Cavity and Phary	<u>ynx</u>		
				Male	3.71	1	NC*
Female	2.26	4	NC*	Female	1.67	2	NC*
				Total	5.38	3	NC*
Colon / Rectum				<u>Ovary</u>			
Male	11.63	8	69				
Female	11.36	14	123	Female	4.20	1	NC*
Total	23.00	22	96				
Esophagus				<u>Pancreas</u>			
Male	1.93	1	NC*	Male	2.09	3	NC*
Female	0.55	1	NC*	Female	2.09	1	NC*
Total	2.48	2	NC*	Total	4.18	4	NC*
Hodgkin's Diseas	e (Hodgkin Lymp	<u>homa)</u>		<u>Prostate</u>			

^{* =} **SIR** and statistical significance not calculated when **Obs** < 5

Male	1.06	0	NC*	Male	31.39	26	83
Female	0.80	3	NC*				
Total	1.85	3	NC*				
Kidney and Renal P	<u>elvis</u>			Stomach			
Male	3.31	4	NC*	Male	2.04	1	NC*
Female	1.99	4	NC*	Female	1.25	0	NC*
Total	5.30	8	151	Total	3.29	1	NC*
<u>Larynx</u>				<u>Testis</u>			
Male	1.90	2	NC*	Male	1.68	2	NC*
Female	0.47	0	NC*				
Total	2.37	2	NC*				
<u>Leukemia</u>				<u>Thyroid</u>			
Male	2.63	4	NC*	Male	0.90	0	NC*
Female	2.11	4	NC*	Female	2.40	3	NC*
Total	4.73	8	169	Total	3.30	3	NC*
Liver and Intrahepa	tic Bile Ducts			Uteri, Corpus and U	terus, NOS		
Male	1.27	1	NC*				
Female	0.48	1	NC*	Female	6.74	3	NC*
Total	1.75	2	NC*				
Lung and Bronchus	<u>s</u>			All Sites / Types			
Male	15.66	8	51	Male	104.27	89	85
Female	13.00	11	85	Female	105.11	102	97
Total	28.65	19	66	Total	209.38	191	91

Obs = observed case count

- + indicates number of observed cases is statistically significantly higher than the expected number of cases
- indicates number of observed cases is statistically significantly lower than the expected number of cases
- # indicates statistical significance at the $p \le 0.05$ level
- ~ indicates statistical significance at the $p \le 0.01$ level, as well as at the $p \le 0.05$ level
- \land indicates statistical significance at the $p \le 0.001$ level, as well as at the $p \le 0.05$ and $p \le 0.01$ levels

PeruExpected and Observed Case Counts, with Standardized Incidence Ratios, 1995 - 1999

	<u>Exp</u>	<u>Obs</u>	<u>SIR</u>		<u>Exp</u>	<u>Obs</u>	SIR
Bladder, Urinary				Melanoma of Skin			
Male	0.53	0	NC*	Male	0.36	0	NC*
Female	0.14	0	NC*	Female	0.24	1	NC*
Total	0.67	0	NC*	Total	0.60	1	NC*
Brain and Other Cen	<u>tral Nervous S</u>	<u>System</u>		Multiple Myeloma			
Male	0.16	0	NC*	Male	0.10	0	NC*
Female	0.12	0	NC*	Female	0.07	0	NC*
Total	0.28	0	NC*	Total	0.17	0	NC*
<u>Breast</u>				Non-Hodgkin('s) Lym	nphoma		
Male	0.03	0	NC*	Male	0.44	0	NC*
Female	2.70	0	NC*	Female	0.30	0	NC*
Total	2.72	0	NC*	Total	0.74	0	NC*
Cervix Uteri				Oral Cavity and Phar	<u>ynx</u>		
				Male	0.34	0	NC*

^{* =} SIR and statistical significance not calculated when **Obs** < 5

Female	0.17	0	NC*	Female	0.13	0	NC*
				Total	0.47	0	NC*
Colon / Rectum				<u>Ovary</u>			
Male	1.31	0	NC*				
Female	0.88	0	NC*	Female	0.32	0	NC*
Total	2.20	0	NC*				
Esophagus				<u>Pancreas</u>			
Male	0.19	0	NC*	Male	0.23	0	NC*
Female	0.04	0	NC*	Female	0.16	0	NC*
Total	0.24	0	NC*	Total	0.39	0	NC*
Hodgkin's Disease (Hodgkin Lymph	<u>ioma)</u>		<u>Prostate</u>			
Male	0.08	0	NC*	Male	3.22	1	NC*
Female	0.06	0	NC*				
Total	0.14	0	NC*				
Kidney and Renal Po	<u>elvis</u>			<u>Stomach</u>			
Male	0.32	0	NC*	Male	0.23	0	NC*
Female	0.16	0	NC*	Female	0.09	0	NC*
Total	0.47	0	NC*	Total	0.32	0	NC*
<u>Larynx</u>				<u>Testis</u>			
Male	0.18	0	NC*	Male	0.12	0	NC*
Female	0.04	0	NC*				
Total	0.22	0	NC*				
<u>Leukemia</u>				<u>Thyroid</u>			
Male	0.26	0	NC*	Male	0.07	0	NC*
Female	0.16	0	NC*	Female	0.18	1	NC*
Total	0.42	0	NC*	Total	0.26	1	NC*
Liver and Intrahepat	ic Bile Ducts			Uteri, Corpus and Ut	erus, NOS		
Male	0.12	0	NC*				
Female	0.04	0	NC*	Female	0.52	0	NC*
Total	0.16	0	NC*				
Lung and Bronchus				All Sites / Types			
Male	1.65	2	NC*	Male	10.68	3	NC*
Female	1.04	0	NC*	Female	8.11	3	NC*
Total	2.68	2	NC*	Total	18.79	6	32 ~-

Obs = observed case count

SIR = standardized incidence ratio [(**Obs** / **Exp**) X 100]

- + indicates number of observed cases is statistically significantly higher than the expected number of cases
- indicates number of observed cases is statistically significantly lower than the expected number of cases
- # indicates statistical significance at the $p \le 0.05$ level
- ~ indicates statistical significance at the $p \le 0.01$ level, as well as at the $p \le 0.05$ level
- \land indicates statistical significance at the $p \le 0.001$ level, as well as at the $p \le 0.05$ and $p \le 0.01$ levels

Petersham Expected and Observed Case Counts, with Standardized Incidence Ratios, 1995 - 1999

	<u>Exp</u>	<u>Obs</u>	<u>SIR</u>		<u>Exp</u>	<u>Obs</u>	SIR
Bladder, Urinary				Melanoma of Skin			
Male	0.91	1	NC*	Male	0.59	0	NC*
Female	0.38	1	NC*	Female	0.44	0	NC*

^{* =} SIR and statistical significance not calculated when **Obs** < 5

Multiple Myeloma Male 0.26 0 NC° Male 0.18 0 NC° Female 0.20 0 NC° Female 0.17 0 NC° Total 0.46 0 NC° Female 0.17 0 NC° Breast Month oldsing's Lymphoma Non-Hodgking's Lymphoma NC° Male 0.71 2 NC° Female 5.50 5 91 Female 0.67 0 NC° Total 5.54 6 108 Total 1.88 0 NC° Female 0.28 1 NC° Female 0.28 0 NC° Female 0.28 0 NC° Female 0.63 2 NC° Female 0.28 0 NC° Female 0.63 2 NC° Female 0.28 0 NC° Female 0.63 0 NC° Female	Total	1.28	2	NC*	Total	1.03	0	NC*
Female	Brain and Other Cen	tral Nervous Sy	<u>stem</u>		Multiple Myeloma			
Total 0.46 0 NC* Total voltable legal by proposal by propertion of the properties	Male	0.26	0	NC*	Male	0.18	0	NC*
Breast Non-Hodskin(*s) Lymbyns Male 0.04 1 NC* Male 0.74 2 NC* Female 5.50 5 91 Female 0.67 0 NC* Cervix Uteri Tempel 0.28 0 NC* Pemale 0.28 0 NC* Female 0.28 1 NC* Pemale 0.28 0 NC* Female 0.28 1 NC* Pemale 0.28 0 NC* Cervix Uteri Tempel 0.28 0 NC* Pemale 0.28 0 NC* Pemale 0.63 2 NC* Pemale 0.23 0 NC* Pemale 0.63 2 NC* Pemale 0.33 0 NC* Pemale 0.33 0 NC* Pemale 0.12 0 NC* Pemale 0.33 <t< td=""><td>Female</td><td>0.20</td><td>0</td><td>NC*</td><td>Female</td><td>0.17</td><td>0</td><td>NC*</td></t<>	Female	0.20	0	NC*	Female	0.17	0	NC*
Male	Total	0.46	0	NC*	Total	0.34	0	NC*
Female 5.50 5 91 Female 0.67 03 NC° Total 5.54 6 108 Total 1.38 2 NC° Cervix Uteri	<u>Breast</u>				Non-Hodgkin('s) Lyn	nphoma		
Total 5.54 6 108 Total 1.38 2 NC° Cervix Uteri	Male	0.04	1	NC*	Male	0.71	2	NC*
Cervix Uteri Oral Cavity and Female 0.28 1 NC* Female 0.26 0 NC* Female 0.28 1 NC* Female 0.28 0 NC* Total 0.84 0.0 NC* Total 0.84 0.0 NC* Emale 2.24 4 NC* Female 0.63 2 NC* Female 2.38 0 NC* Female 0.63 2 NC* Total 4.62 4 NC* Female 0.63 2 NC* Female 0.12 0 NC* Female 0.38 0 NC* Female 0.12 0 NC* Total 0.81 2 NC* Total 0.44 0 NC* Total 0.81 2 NC* Male 0.12 0 NC* Male 0.55 7 126 Female 0.32 0 NC*	Female	5.50	5	91	Female	0.67	0	NC*
Pemale 0.28	Total	5.54	6	108	Total	1.38	2	NC*
Female 0.28 1 NC* Female 0.28 0 NC* Colon / Rectum Oyary Male 2.24 4 NC* Female 0.63 2 NC* Female 2.38 0 NC* Female 0.63 2 NC* Total 4.62 4 NC* Female 0.63 2 NC* Esophagus Pancreas Male 0.32 0 NC* Male 0.43 2 NC* Female 0.12 0 NC* Female 0.43 2 NC* Hodgkin's Disease (Hodykin Lymphoma) Prostate Male 0.12 0 NC* Male 5.55 7 126 Female 0.09 0 NC* Male 0.53 2 NC* Female 0.34 0 NC* Female 0.26 NC* Female 0.34 0	Cervix Uteri				Oral Cavity and Phar	rynx_		
Colon / Rectum Douny Male 2.24 4 NC* Female 2.38 0 NC* Female 0.63 2 NC* Total 4.62 4 NC* Female 0.63 2 NC* Esophagus Pancreas Male 0.32 0 NC* Male 0.38 0 NC* Female 0.12 0 NC* Female 0.43 2 NC* Total 0.44 0 NC* Total 0.43 2 NC* Hodgkin's Disease (Hotylin Lymphoma) Pemale 0.44 0 NC* Male 5.55 7 126 Hodgkin's Disease (Hotylin Lymphoma) Protestal Male 0.12 0 NC* Male 5.55 7 126 Female 0.53 2 NC* Male 0.38 0 NC* Female 0.34 0					Male	0.56	0	NC*
Colon / Rectum Covary Male 2.24 4 NC* Female 0.63 2 NC* Female 2.38 0 NC* Female 0.63 2 NC* Total 4.62 4 NC* Total 0.38 0 NC* Male 0.32 0 NC* Male 0.38 0 NC* Female 0.12 0 NC* Female 0.43 2 NC* Total 0.44 0 NC* Total 0.81 2 NC* Male 0.12 0 NC* Total 0.81 2 NC* Female 0.09 0 NC*	Female	0.28	1	NC*	Female	0.28	0	NC*
Male 2.24 4 NC* Female 0.63 2 NC* Female 2.38 0 NC* Female 0.63 2 NC* Total 4.62 4 NC* Male 0.38 0 NC* Male 0.32 0 NC* Male 0.38 0 NC* Female 0.12 0 NC* Female 0.43 2 NC* Hodgkin's Disease (Hodgkin Lymphoma) Prostate Male 0.12 0 NC* Male 5.55 7 126 Female 0.09 0 NC* Male 5.55 7 126 Female 0.09 0 NC* Stomach NC*					Total	0.84	0	NC*
Female 2.38 0 NC* Female 0.63 2 NC* Total 4.62 4 NC* Female 0.38 0 NC* Esophagus Pancreas Male 0.32 0 NC* Male 0.43 2 NC* Female 0.12 0 NC* Female 0.43 2 NC* Hodgkin's Disease (Hodgkin Lymphoma) Prostate Male 0.12 0 NC* Male 5.55 7 126 Female 0.09 0 NC* Male 5.55 7 126 Female 0.09 0 NC* Male 0.38 0 NC* Male 0.53 2 NC* Male 0.38 0 NC* Female 0.34 0 NC* Female 0.26 0 NC* Female 0.30 0 NC* Male 0.17	Colon / Rectum				<u>Ovary</u>			
Total 4.62 4 NC* Pancreas Esophagus Pancreas NC* Male 0.38 0 NC* Female 0.12 0 NC* Female 0.43 2 NC* Total 0.44 0 NC* Total 0.81 2 NC* Male 0.12 0 NC* Male 5.55 7 126 Female 0.09 0 NC* Male 5.55 7 126 Female 0.09 0 NC* NC* NC* 126 NC* 126 NC* NC* 126 NC* 126 NC* 126 NC* 126 NC*	Male	2.24	4	NC*				
Esophagus Pancreas Male 0.32 0 NC* Male 0.38 0 NC* Female 0.12 0 NC* Temale 0.43 2 NC* Total 0.44 0 NC* Total 0.81 2 NC* Hodgkin's Disease (Hodgkin Lymphoma) "Prostate" "Total" 0.12 0 NC* Male 5.55 7 126 Female 0.09 0 NC*	Female	2.38	0	NC*	Female	0.63	2	NC*
Male 0.32 0 NC* Male 0.38 0 NC* Female 0.12 0 NC* Female 0.43 2 NC* Total 0.44 0 NC* Total 0.81 2 NC* Hodgkin's Disease (Hodgkin Lymphoms) Prostate Male 0.12 0 NC* Male 5.55 7 126 Female 0.09 0 NC* Male 5.55 7 126 Female 0.09 0 NC* NC* Male 0.38 0 NC* Female 0.53 2 NC* Male 0.38 0 NC* Female 0.34 0 NC* Female 0.26 0 NC* Female 0.37 0 NC* Total 0.64 0 NC* Female 0.30 0 NC* Male 0.17 0 NC* <td< td=""><td>Total</td><td>4.62</td><td>4</td><td>NC*</td><td></td><td></td><td></td><td></td></td<>	Total	4.62	4	NC*				
Female 0.12 0 NC* Female 0.43 2 NC* Hodgkin's Disease (Hodgkin Lymphoma) Prostate Male 0.12 0 NC* Male 5.55 7 126 Female 0.09 0 NC* Male 5.55 7 126 Female 0.09 0 NC* Male 5.55 7 126 Female 0.09 0 NC* Male 5.55 7 126 Kidney and Renal Petus Stomach Stomach Kidney and Renal Petus Stomach Stomach Male 0.53 2 NC* Male 0.38 0 NC* Female 0.34 0 NC* Female 0.10 NC* Jame 0.08 0 NC* Male 0.17 0 NC* Female 0.41 0 NC* Female 0.27 0 NC*	Esophagus				<u>Pancreas</u>			
Total 0.44 0 NC* Total 0.81 2 NC* Hodgkin's Disease (Hodgkin Lymphoma) Prostate Prostate 3 126 Male 0.12 0 NC* Male 5.55 7 126 Female 0.09 0 NC* Male 5.55 7 126 Female 0.09 0 NC*	Male	0.32	0	NC*	Male	0.38	0	NC*
Hodgkin's Disease (Hodgkin Lymphoma) Prostate Male 0.12 0 NC* Male 5.55 7 126 Female 0.09 0 NC* ————————————————————————————————————	Female	0.12	0	NC*	Female	0.43	2	NC*
Male 0.12 0 NC* Male 5.55 7 126 Female 0.09 0 NC* NC* Image: Control of the control of	Total	0.44	0	NC*	Total	0.81	2	NC*
Female Total 0.09 0 NC* Kidney and Renal Pelvis Stomach Male 0.53 2 NC* Male 0.38 0 NC* Female 0.34 0 NC* Female 0.26 0 NC* Total 0.87 2 NC* Total 0.64 0 NC* Male 0.30 0 NC* Male 0.17 0 NC* Female 0.08 0 NC* Male 0.17 0 NC* Female 0.08 0 NC* Male 0.17 0 NC* Female 0.08 0 NC* Male 0.11 0 NC* Leukemia 0.41 0 NC* Female 0.27 0 NC* Female 0.33 0 NC* Female 0.27 0 NC* Iver and Intrahepatic Bie Ducts 0 NC* Female </td <td>Hodgkin's Disease (F</td> <td>lodgkin Lymph</td> <td><u>oma)</u></td> <td></td> <td>Prostate</td> <td></td> <td></td> <td></td>	Hodgkin's Disease (F	lodgkin Lymph	<u>oma)</u>		Prostate			
Total 0.21 0 NC* Stomach Male 0.53 2 NC* Male 0.38 0 NC* Female 0.34 0 NC* Female 0.26 0 NC* Total 0.87 2 NC* Total 0.64 0 NC* Male 0.30 0 NC* Male 0.17 0 NC* Female 0.08 0 NC* Male 0.17 0 NC* Female 0.08 0 NC* Male 0.17 0 NC* Female 0.08 0 NC* Male 0.11 0 NC* Female 0.33 0 NC* Female 0.27 0 NC* Total 0.75 0 NC* Total 0.38 0 NC* Male 0.20 NC* Female 1.07 1 NC*	Male	0.12	0	NC*	Male	5.55	7	126
Kidney and Renal Pelvis Stomach Male 0.53 2 NC* Male 0.38 0 NC* Female 0.34 0 NC* Female 0.26 0 NC* Total 0.87 2 NC* Total 0.64 0 NC* Male 0.30 0 NC* Male 0.17 0 NC* Female 0.08 0 NC* Male 0.17 0 NC* Total 0.38 0 NC* NC* <td>Female</td> <td>0.09</td> <td>0</td> <td>NC*</td> <td></td> <td></td> <td></td> <td></td>	Female	0.09	0	NC*				
Male 0.53 2 NC* Male 0.38 0 NC* Female 0.34 0 NC* Female 0.26 0 NC* Total 0.87 2 NC* Total 0.64 0 NC* Lerynx Testis Male 0.30 0 NC* Male 0.17 0 NC* Female 0.08 0 NC* Male 0.17 0 NC* Female 0.08 0 NC* Total 0.11 0 NC* Leukemia Thyroid Male 0.41 0 NC* Female 0.27 0 NC* Female 0.33 0 NC* Total 0.38 0 NC* Liver and Intrahepatic Bile Ducts Uteri, Corpus and Uterus, NOS Male 0.20 0 NC* Female 1.07 1 NC* Total 0.30	Total	0.21	0	NC*				
Female 0.34 0 NC* Female 0.26 0 NC* Total 0.87 2 NC* Total 0.64 0 NC* Larynx Testis Male 0.30 0 NC* Male 0.17 0 NC* Female 0.08 0 NC* Male 0.17 0 NC* Female 0.08 0 NC* Thyroid Total 0.11 0 NC* Male 0.41 0 NC* Female 0.27 0 NC* Female 0.33 0 NC* Female 0.27 0 NC* Total 0.75 0 NC* Total 0.38 0 NC* Male 0.20 0 NC* Female 1.07 1 NC* Female 0.09 0 NC* Female 1.07 1 NC* Lung and Bronchus	Kidney and Renal Pe	<u>lvis</u>			Stomach			
Total 0.87 2 NC* Total 0.64 0 NC* Larynx Testis Male 0.30 0 NC* Male 0.17 0 NC* Female 0.08 0 NC* Male 0.17 0 NC* Total 0.38 0 NC* Male 0.11 0 NC* Female 0.41 0 NC* Female 0.27 0 NC* Female 0.33 0 NC* Female 0.27 0 NC* Total 0.75 0 NC* Total 0.38 0 NC* Eiver and Intrahepatic Bile Ducts Uteri, Corpus and Uterus, NOS Male 0.20 NC* Female 1.07 1 NC* Female 0.09 0 NC* Female 1.07 1 NC* Lung and Bronchus All Sites / Types Male 2.84 </td <td>Male</td> <td>0.53</td> <td>2</td> <td>NC*</td> <td>Male</td> <td>0.38</td> <td>0</td> <td>NC*</td>	Male	0.53	2	NC*	Male	0.38	0	NC*
Larynx Testis Male 0.30 0 NC* Male 0.17 0 NC* Female 0.08 0 NC* Female 0.17 0 NC* Total 0.38 0 NC* Temproid 0.11 0 NC* Male 0.41 0 NC* Male 0.11 0 NC* Female 0.33 0 NC* Female 0.27 0 NC* Total 0.75 0 NC* Total 0.38 0 NC* Liver and Intrahepatic Bile Ducts Utteri, Corpus and Uterus, NOS Male 0.20 0 NC* Female 1.07 1 NC* Female 0.09 0 NC* Female 1.07 1 NC* Lung and Bronchus All Sites / Types Male 2.84 2 NC* Male 18.01 19 105 Female	Female	0.34	0	NC*	Female	0.26	0	NC*
Male 0.30 0 NC* Male 0.17 0 NC* Female 0.08 0 NC* Total 0.38 0 NC* Very Companies Very Companies Very Companies Very Companies NC* Total 0.11 0 NC*	Total	0.87	2	NC*	Total	0.64	0	NC*
Female Total 0.08 0 NC* Total 0.38 0 NC* Leukemia Thyroid Male 0.41 0 NC* Male 0.11 0 NC* Female 0.33 0 NC* Female 0.27 0 NC* Total 0.75 0 NC* Total 0.38 0 NC* Male 0.20 0 NC* Female 1.07 1 NC* Female 0.09 0 NC* Female 1.07 1 NC* Lung and Bronchus All Sites / Types Male 2.84 2 NC* Male 18.01 19 105 Female 2.36 1 NC* Female 17.72 16 90	<u>Larynx</u>				<u>Testis</u>			
Total 0.38 0 NC* Leukemia Thyroid Male 0.41 0 NC* Male 0.11 0 NC* Female 0.33 0 NC* Female 0.27 0 NC* Total 0.75 0 NC* Total 0.38 0 NC* Male 0.20 0 NC* Female 1.07 1 NC* Female 0.09 0 NC* Female 1.07 1 NC* Lung and Bronchus All Sites / Types Male 2.84 2 NC* Male 18.01 19 105 Female 2.36 1 NC* Female 17.72 16 90	Male	0.30	0	NC*	Male	0.17	0	NC*
Leukemia Thyroid Male 0.41 0 NC* Male 0.11 0 NC* Female 0.33 0 NC* Female 0.27 0 NC* Total 0.75 0 NC* Total 0.38 0 NC* Liver and Intrahepatic Bile Ducts Uteri, Corpus and Uterus, NOS Male 0.20 0 NC* Female 1.07 1 NC* Female 0.09 0 NC* Female 1.07 1 NC* Lung and Bronchus All Sites / Types Male 2.84 2 NC* Male 18.01 19 105 Female 2.36 1 NC* Female 17.72 16 90	Female	0.08	0	NC*				
Male 0.41 0 NC* Male 0.11 0 NC* Female 0.33 0 NC* Female 0.27 0 NC* Total 0.75 0 NC* Total 0.38 0 NC* Liver and Intrahepatic Bile Ducts Uteri, Corpus and Uterus, NOS Male 0.20 0 NC* Female 1.07 1 NC* Female 0.09 0 NC* Female 1.07 1 NC* Total 0.30 0 NC* All Sites / Types NC*	Total	0.38	0	NC*				
Female 0.33 0 NC* Female 0.27 0 NC* Total 0.75 0 NC* Total 0.38 0 NC* Liver and Intrahepatic Bile Ducts Uteri, Corpus and Uterus, NOS Male 0.20 0 NC* Female 1.07 1 NC* Female 0.30 0 NC* Female 1.07 1 NC* Lung and Bronchus All Sites / Types Male 2.84 2 NC* Male 18.01 19 105 Female 2.36 1 NC* Female 17.72 16 90	<u>Leukemia</u>				<u>Thyroid</u>			
Total 0.75 0 NC* Total 0.38 0 NC* Liver and Intrahepatic Bile Ducts Uteri, Corpus and Uterus, NOS Male 0.20 0 NC* Female 1.07 1 NC* Female 0.30 0 NC* Female 1.07 1 NC* Lung and Bronchus All Sites / Types Male 2.84 2 NC* Male 18.01 19 105 Female 2.36 1 NC* Female 17.72 16 90	Male	0.41	0	NC*	Male	0.11	0	NC*
Liver and Intrahepatic Bile Ducts Uteri, Corpus and Uterus, NOS Male 0.20 0 NC* Female 0.09 0 NC* Female 1.07 1 NC* Total 0.30 0 NC* All Sites / Types Lung and Bronchus All Sites / Types Male 2.84 2 NC* Male 18.01 19 105 Female 2.36 1 NC* Female 17.72 16 90	Female	0.33	0	NC*	Female	0.27	0	NC*
Male 0.20 0 NC* Female 0.09 0 NC* Female 1.07 1 NC* Total 0.30 0 NC* All Sites / Types Lung and Bronchus Male 2.84 2 NC* Male 18.01 19 105 Female 2.36 1 NC* Female 17.72 16 90	Total	0.75	0	NC*	Total	0.38	0	NC*
Female 0.09 0 NC* Female 1.07 1 NC* Total 0.30 0 NC* All Sites / Types VEX. VEX. Male 18.01 19 105 Male 2.36 1 NC* Female 17.72 16 90	Liver and Intrahepati	c Bile Ducts			Uteri, Corpus and Ut	terus, NOS		
Total 0.30 0 NC* Lung and Bronchus All Sites / Types Male 2.84 2 NC* Male 18.01 19 105 Female 2.36 1 NC* Female 17.72 16 90	Male	0.20	0	NC*				
Lung and Bronchus Male 2.84 2 NC* Male 18.01 19 105 Female 2.36 1 NC* Female 17.72 16 90	Female	0.09	0	NC*	Female	1.07	1	NC*
Male 2.84 2 NC* Male 18.01 19 105 Female 2.36 1 NC* Female 17.72 16 90	Total	0.30	0	NC*				
Female 2.36 1 NC* Female 17.72 16 90	Lung and Bronchus				All Sites / Types			
	Male	2.84	2	NC*	Male	18.01	19	105
	Female	2.36	1	NC*	Female	17.72	16	90
Total 5.20 3 NC* Total 35.73 35 98	Total	5.20	3	NC*	Total	35.73	35	98

Obs = observed case count

^{* =} **SIR** and statistical significance not calculated when **Obs** < 5

⁺ indicates number of observed cases is statistically significantly higher than the expected number of cases

⁻ indicates number of observed cases is statistically significantly lower than the expected number of cases

- ~ indicates statistical significance at the $p \le 0.01$ level, as well as at the $p \le 0.05$ level
- \land indicates statistical significance at the $p \le 0.001$ level, as well as at the $p \le 0.05$ and $p \le 0.01$ levels

Phillipston
Expected and Observed Case Counts, with Standardized Incidence Ratios, 1995 - 1999

	<u>Exp</u>	<u>Obs</u>	SIR		<u>Exp</u>	<u>Obs</u>	SIR
Bladder, Urinary				Melanoma of Skin			
Male	0.93	0	NC*	Male	0.74	0	NC*
Female	0.24	0	NC*	Female	0.48	0	NC*
Total	1.17	0	NC*	Total	1.22	0	NC*
Brain and Other Cen	tral Nervous S	<u>iystem</u>		Multiple Myeloma			
Male	0.36	1	NC*	Male	0.19	0	NC*
Female	0.23	0	NC*	Female	0.12	1	NC*
Total	0.59	1	NC*	Total	0.32	1	NC*
<u>Breast</u>				Non-Hodgkin('s) Lym	<u>phoma</u>		
Male	0.05	0	NC*	Male	0.88	1	NC*
Female	5.31	1	NC*	Female	0.56	0	NC*
Total	5.36	1	NC*	Total	1.44	1	NC*
Cervix Uteri				Oral Cavity and Phary	<u>ynx</u>		
				Male	0.71	0	NC*
Female	0.37	0	NC*	Female	0.24	0	NC*
				Total	0.95	0	NC*
Colon / Rectum				<u>Ovary</u>			
Male	2.36	1	NC*				
Female	1.53	0	NC*	Female	0.64	0	NC*
Total	3.89	1	NC*				
<u>Esophagus</u>				<u>Pancreas</u>			
Male	0.38	0	NC*	Male	0.42	0	NC*
Female	0.07	0	NC*	Female	0.28	0	NC*
Total	0.45	0	NC*	Total	0.70	0	NC*
Hodgkin's Disease (I	Hodgkin Lymp	homa)		<u>Prostate</u>			
Male	0.20	0	NC*	Male	6.37	4	NC*
Female	0.14	1	NC*				
Total	0.33	1	NC*				
Kidney and Renal Pe	lvis			Stomach			
Male	0.64	0	NC*	Male	0.41	0	NC*
Female	0.29	0	NC*	Female	0.17	0	NC*
Total	0.93	0	NC*	Total	0.58	0	NC*
<u>Larynx</u>				<u>Testis</u>			
Male	0.37	1	NC*	Male	0.31	1	NC*
Female	0.07	0	NC*				
Total	0.44	1	NC*				
<u>Leukemia</u>				<u>Thyroid</u>			
Male	0.50	0	NC*	Male	0.17	0	NC*
Female	0.31	0	NC*	Female	0.41	0	NC*
Total	0.81	0	NC*	Total	0.58	0	NC*
Liver and Intrahepati				Uteri, Corpus and Ute			
Male	0.25	0	NC*				
Female	0.07	0	NC*	Female	1.00	0	NC*
Total	0.31	0	NC*				-
Lung and Bronchus				All Sites / Types			

Male	3.16	1	NC*	Male	20.77	11	53 #-
Female	1.90	2	NC*	Female	15.46	6	39 #-
Total	5.06	3	NC*	Total	36.23	17	47 ^-

Obs = observed case count

- + indicates number of observed cases is statistically significantly higher than the expected number of cases
- indicates number of observed cases is statistically significantly lower than the expected number of cases # indicates statistical significance at the $\mathbf{p} \leq 0.05$ level
- ~ indicates statistical significance at the $p \le 0.01$ level, as well as at the $p \le 0.05$ level
- \land indicates statistical significance at the $p \le 0.001$ level, as well as at the $p \le 0.05$ and $p \le 0.01$ levels

Pittsfield
Expected and Observed Case Counts, with Standardized Incidence Ratios, 1995 - 1999

	<u>Exp</u>	<u>Obs</u>	SIR		Exp	<u>Obs</u>	<u>SIR</u>
Bladder, Urinary				Melanoma of Skin			
Male	36.46	28	77	Male	22.34	16	72
Female	15.43	14	91	Female	17.80	12	67
Total	51.88	42	81	Total	40.14	28	70
Brain and Other Ce	entral Nervous S	<u>System</u>		Multiple Myeloma			
Male	9.65	9	93	Male	6.88	10	145
Female	8.51	6	71	Female	6.68	4	NC*
Total	18.15	15	83	Total	13.56	14	103
<u>Breast</u>				Non-Hodgkin('s) Lyı	mphoma		
Male	1.65	1	NC*	Male	27.40	18	66
Female	217.96	226	104	Female	27.74	17	61 #-
Total	219.61	227	103	Total	55.14	35	63 ~-
Cervix Uteri				Oral Cavity and Pha	<u>rynx</u>		
				Male	20.47	15	73
Female	11.32	13	115	Female	11.24	3	NC*
				Total	31.71	18	57 #-
Colon / Rectum				<u>Ovary</u>			
Male	89.61	85	95				
Female	97.11	75	77 #-	Female	25.16	28	111
Total	186.72	160	86				
Esophagus				<u>Pancreas</u>			
Male	12.24	9	74	Male	14.81	21	142
Female	4.74	3	NC*	Female	17.81	10	56
Total	16.98	12	71	Total	32.62	31	95
Hodgkin's Disease	(Hodgkin Lymp	ohoma)		<u>Prostate</u>			
Male	4.64	4	NC*	Male	215.29	168	78 ^-
Female	3.83	1	NC*				
Total	8.47	5	59				
Kidney and Renal I	<u>Pelvis</u>			<u>Stomach</u>			
Male	19.90	13	65	Male	15.06	10	66
Female	13.83	9	65	Female	10.52	8	76
Total	33.72	22	65 #-	Total	25.58	18	70
<u>Larynx</u>				<u>Testis</u>			
Male	11.24	10	89	Male	6.82	4	NC*

^{* =} **SIR** and statistical significance not calculated when **Obs** < 5

Female	3.09	4	NC*				
Total	14.34	14	98				
<u>Leukemia</u>				Thyroid			
Male	16.23	15	92	Male	4.09	3	NC*
Female	13.77	6	44 #-	Female	11.18	11	98
Total	29.99	21	70	Total	15.28	14	92
Liver and Intrahepa	atic Bile Ducts			Uteri, Corpus and L	Iterus, NOS		
Male	7.72	3	NC*				
Female	3.82	3	NC*	Female	42.36	34	80
Total	11.54	6	52				
Lung and Bronchu	<u>is</u>			All Sites / Types			
Male	111.39	94	84	Male	701.74	584	83 ^-
Female	96.82	83	86	Female	715.26	606	85 ^-
Total	208.21	177	85 #-	Total	1417.00	1190	84 ^-

Obs = observed case count

- + indicates number of observed cases is statistically significantly higher than the expected number of cases
- indicates number of observed cases is statistically significantly lower than the expected number of cases
- # indicates statistical significance at the $\mathbf{p} \leq 0.05$ level
- ~ indicates statistical significance at the $p \le 0.01$ level, as well as at the $p \le 0.05$ level
- \land indicates statistical significance at the **p** \leq 0.001 level, as well as at the **p** \leq 0.05 and **p** \leq 0.01 levels

Plainfield
Expected and Observed Case Counts, with Standardized Incidence Ratios, 1995 - 1999

	•		•		·		
	<u>Exp</u>	<u>Obs</u>	<u>SIR</u>		<u>Exp</u>	<u>Obs</u>	SIR
Bladder, Urinary				Melanoma of Skin			
Male	0.46	0	NC*	Male	0.29	0	NC*
Female	0.13	0	NC*	Female	0.18	0	NC*
Total	0.59	0	NC*	Total	0.46	0	NC*
Brain and Other Cer	ntral Nervous S	<u>System</u>		Multiple Myeloma			
Male	0.12	0	NC*	Male	0.09	0	NC*
Female	0.09	0	NC*	Female	0.06	0	NC*
Total	0.21	0	NC*	Total	0.15	0	NC*
<u>Breast</u>				Non-Hodgkin('s) Lym	<u>nphoma</u>		
Male	0.02	0	NC*	Male	0.34	0	NC*
Female	2.25	4	NC*	Female	0.25	0	NC*
Total	2.28	4	NC*	Total	0.60	0	NC*
Cervix Uteri				Oral Cavity and Phar	<u>ynx</u>		
				Male	0.27	0	NC*
Female	0.12	0	NC*	Female	0.11	0	NC*
				Total	0.38	0	NC*
Colon / Rectum				<u>Ovary</u>			
Male	1.14	0	NC*				
Female	0.79	0	NC*	Female	0.26	0	NC*
Total	1.93	0	NC*				
Esophagus				<u>Pancreas</u>			
Male	0.16	0	NC*	Male	0.19	0	NC*
Female	0.04	0	NC*	Female	0.15	0	NC*

^{* =} **SIR** and statistical significance not calculated when **Obs** < 5

Total	0.20	0	NC*	Total	0.34	0	NC*
Hodgkin's Disease (Hodgkin Lymph	oma)		Prostate			
Male	0.05	0	NC*	Male	2.77	2	NC*
Female	0.04	0	NC*				
Total	0.09	0	NC*				
Kidney and Renal P	<u>elvis</u>			Stomach			
Male	0.26	0	NC*	Male	0.19	0	NC*
Female	0.13	0	NC*	Female	0.08	0	NC*
Total	0.40	0	NC*	Total	0.27	0	NC*
<u>Larynx</u>				<u>Testis</u>			
Male	0.15	0	NC*	Male	0.07	0	NC*
Female	0.03	0	NC*				
Total	0.18	0	NC*				
<u>Leukemia</u>				<u>Thyroid</u>			
Male	0.21	0	NC*	Male	0.05	0	NC*
Female	0.13	0	NC*	Female	0.12	0	NC*
Total	0.33	0	NC*	Total	0.17	0	NC*
Liver and Intrahepat	ic Bile Ducts			Uteri, Corpus and Ut	terus, NOS		
Male	0.10	0	NC*				
Female	0.03	0	NC*	Female	0.45	0	NC*
Total	0.13	0	NC*				
Lung and Bronchus				All Sites / Types			
Male	1.43	1	NC*	Male	8.97	3	NC*
Female	0.94	0	NC*	Female	6.85	4	NC*
Total	2.37	1	NC*	Total	15.82	7	44 #-

Obs = observed case count

- + indicates number of observed cases is statistically significantly higher than the expected number of cases
- indicates number of observed cases is statistically significantly lower than the expected number of cases # indicates statistical significance at the $\mathbf{p} \leq 0.05$ level
- ~ indicates statistical significance at the $p \le 0.01$ level, as well as at the $p \le 0.05$ level
- \land indicates statistical significance at the $p \le 0.001$ level, as well as at the $p \le 0.05$ and $p \le 0.01$ levels

Plainville
Expected and Observed Case Counts, with Standardized Incidence Ratios, 1995 - 1999

	<u>Exp</u>	<u>Obs</u>	<u>SIR</u>		<u>Exp</u>	<u>Obs</u>	SIR	
Bladder, Urinary				Melanoma of Skin				
Male	4.38	7	160	Male	3.18	3	NC*	
Female	1.87	2	NC*	Female	2.59	3	NC*	
Total	6.25	9	144	Total	5.77	6	104	
Brain and Other Central Nervous System				Multiple Myeloma				
Male	1.47	4	NC*	Male	0.88	1	NC*	
Female	1.21	2	NC*	Female	0.84	1	NC*	
Total	2.68	6	224	Total	1.72	2	NC*	
<u>Breast</u>				Non-Hodgkin('s) Lymphoma				
Male	0.21	1	NC*	Male	3.81	3	NC*	
Female	30.48	22	72	Female	3.60	3	NC*	
Total	30.69	23	75	Total	7.41	6	81	

^{* =} SIR and statistical significance not calculated when **Obs** < 5

Cervix Uteri		Oral Cavity and Pharynx					
				Male	2.97	0	NC*
Female	1.79	2	NC*	Female	1.50	1	NC*
				Total	4.47	1	NC*
Colon / Rectum				<u>Ovary</u>			
Male	10.97	10	91				
Female	11.72	10	85	Female	3.57	1	NC*
Total	22.69	20	88				
Esophagus				<u>Pancreas</u>			
Male	1.65	2	NC*	Male	1.89	0	NC*
Female	0.57	0	NC*	Female	2.16	1	NC*
Total	2.22	2	NC*	Total	4.04	1	NC*
Hodgkin's Disease	(Hodgkin Lympl	homa)		<u>Prostate</u>			
Male	0.80	1	NC*	Male	27.82	22	79
Female	0.62	2	NC*				
Total	1.41	3	NC*				
Kidney and Renal Pelvis				Stomach			
Male	2.74	2	NC*	Male	1.88	0	NC*
Female	1.82	1	NC*	Female	1.28	0	NC*
Total	4.56	3	NC*	Total	3.17	0	NC*
<u>Larynx</u>				Testis			
Male	1.56	1	NC*	 Male	1.28	1	NC*
Female	0.42	0	NC*				
Total	1.98	1	NC*				
<u>Leukemia</u>				<u>Thyroid</u>			
Male	2.19	0	NC*	Male	0.69	1	NC*
Female	1.84	2	NC*	Female	1.84	3	NC*
Total	4.04	2	NC*	Total	2.53	4	NC*
Liver and Intrahepa		_		Uteri, Corpus and U		·	
Male	1.06	1	NC*				
Female	0.47	0	NC*	Female	5.83	4	NC*
Total	1.54	1	NC*		0.00	·	
Lung and Bronchus		·		All Sites / Types			
Male	<u>2</u> 14.13	26	184 ~+	Male	91.81	88	96
Female	12.36	14	113	Female	95.28	84	88
Total	26.49	40	151 #+	Total	187.09	172	92

Obs = observed case count

SIR = standardized incidence ratio [(Obs / Exp) X 100]

- + indicates number of observed cases is statistically significantly higher than the expected number of cases
- indicates number of observed cases is statistically significantly lower than the expected number of cases # indicates statistical significance at the $\mathbf{p} \leq 0.05$ level
- ~ indicates statistical significance at the $p \le 0.01$ level, as well as at the $p \le 0.05$ level
- \land indicates statistical significance at the $\mathbf{p} \le 0.001$ level, as well as at the $\mathbf{p} \le 0.05$ and $\mathbf{p} \le 0.01$ levels

Plymouth

Expected and Observed Case Counts, with Standardized Incidence Ratios, 1995 - 1999

<u>Exp</u> <u>Obs</u> <u>SIR</u> <u>Exp</u> <u>Obs</u> <u>SIR</u> <u>Bladder, Urinary</u> <u>Melanoma of Skin</u>

^{* =} SIR and statistical significance not calculated when **Obs** < 5

Male	28.50	38	133	Male	20.20	30	148 #+
Female	11.29	17	151	Female	15.83	11	69
Total	39.79	55	138 #+	Total	36.04	41	114
Brain and Other Central Nervous System				Multiple Myeloma			
Male	9.28	11	119	Male	5.70	10	175
Female	7.51	9	120	Female	5.12	9	176
Total	16.79	20	119	Total	10.83	19	175 #+
Breast				Non-Hodgkin('s) Ly			
Male	1.37	0	NC*	Male	24.27	19	78
Female	186.62	183	98	Female	21.84	28	128
Total	188.00	183	97	Total	46.11	47	102
Cervix Uteri				Oral Cavity and Pha	aryn <u>x</u>		
				Male	19.02	24	126
Female	10.89	16	147	Female	9.16	13	142
				Total	28.18	37	131
Colon / Rectum				<u>Ovary</u>			
Male	70.92	80	113				
Female	71.05	65	91	Female	21.83	15	69
Total	141.97	145	102				
Esophagus				<u>Pancreas</u>			
Male	10.57	8	76	Male	12.16	9	74
Female	3.43	2	NC*	Female	12.94	12	93
Total	14.00	10	71	Total	25.10	21	84
Hodgkin's Disease (Hodgkin Lymphoma)			Prostate				
Male	4.82	8	166	Male	176.64	183	104
Female	3.75	3	NC*				
Total	8.57	11	128				
Kidney and Renal	<u>Pelvis</u>			Stomach			
Male	17.67	21	119	Male	12.24	14	114
Female	11.05	12	109	Female	7.74	4	NC*
Total	28.72	33	115	Total	19.98	18	90
<u>Larynx</u>				<u>Testis</u>			
Male	10.00	8	80	Male	7.40	10	135
Female	2.52	4	NC*				
Total	12.52	12	96				
<u>Leukemia</u>				<u>Thyroid</u>			
Male	14.19	12	85	Male	4.20	3	NC*
Female	11.42	13	114	Female	11.22	11	98
Total	25.61	25	98	Total	15.42	14	91
Liver and Intrahepa	atic Bile Ducts			Uteri, Corpus and L	<u> Iterus, NOS</u>		
Male	6.80	5	73				
Female	2.86	1	NC*	Female	35.74	31	87
Total	9.66	6	62				
Lung and Bronchu				All Sites / Types			
Male	90.44	101	112	Male	586.47	634	108
Female	74.52	87	117	Female	580.62	584	101
Total	164.97	188	114	Total	1167.10	1218	104

Obs = observed case count

 $^{^{\}star}$ = SIR and statistical significance not calculated when **Obs** < 5

⁺ indicates number of observed cases is statistically significantly higher than the expected number of cases

- indicates number of observed cases is statistically significantly lower than the expected number of cases # indicates statistical significance at the $\mathbf{p} \leq 0.05$ level
- ~ indicates statistical significance at the $p \le 0.01$ level, as well as at the $p \le 0.05$ level
- \land indicates statistical significance at the $p \le 0.001$ level, as well as at the $p \le 0.05$ and $p \le 0.01$ levels

Plympton
Expected and Observed Case Counts, with Standardized Incidence Ratios, 1995 - 1999

	Exp	<u>Obs</u>	SIR		Exp	<u>Obs</u>	SIR
Bladder, Urinary				Melanoma of Skin			
Male	1.27	2	NC*	Male	1.05	1	NC*
Female	0.47	0	NC*	Female	0.79	0	NC*
Total	1.74	2	NC*	Total	1.85	1	NC*
Brain and Other Cen	tral Nervous S	<u>System</u>		Multiple Myeloma			
Male	0.50	0	NC*	Male	0.28	0	NC*
Female	0.37	1	NC*	Female	0.24	1	NC*
Total	0.87	1	NC*	Total	0.52	1	NC*
<u>Breast</u>				Non-Hodgkin('s) Lym	<u>nphoma</u>		
Male	0.07	0	NC*	Male	1.22	0	NC*
Female	9.72	8	82	Female	1.00	2	NC*
Total	9.79	8	82	Total	2.21	2	NC*
Cervix Uteri				Oral Cavity and Phar	<u>ynx</u>		
				Male	1.06	0	NC*
Female	0.57	0	NC*	Female	0.45	0	NC*
				Total	1.51	0	NC*
Colon / Rectum				<u>Ovary</u>			
Male	3.26	4	NC*				
Female	2.90	3	NC*	Female	1.13	1	NC*
Total	6.16	7	114				
Esophagus				<u>Pancreas</u>			
Male	0.56	0	NC*	Male	0.59	0	NC*
Female	0.14	0	NC*	Female	0.54	0	NC*
Total	0.70	0	NC*	Total	1.14	0	NC*
Hodgkin's Disease (Hodgkin Lymp	homa <u>)</u>		Prostate			
Male	0.25	0	NC*	Male	9.24	4	NC*
Female	0.18	0	NC*				
Total	0.43	0	NC*				
Kidney and Renal Pe	<u>elvis</u>			Stomach			
Male	0.94	1	NC*	Male	0.57	0	NC*
Female	0.54	0	NC*	Female	0.31	0	NC*
Total	1.48	1	NC*	Total	0.88	0	NC*
<u>Larynx</u>				<u>Testis</u>			
Male	0.56	0	NC*	Male	0.37	0	NC*
Female	0.13	0	NC*				
Total	0.69	0	NC*				
<u>Leukemia</u>				<u>Thyroid</u>			
Male	0.69	1	NC*	Male	0.24	0	NC*
Female	0.52	0	NC*	Female	0.58	0	NC*
Total	1.21	1	NC*	Total	0.81	0	NC*
Liver and Intrahepatic Bile Ducts			Uteri, Corpus and Uterus, NOS				
Male	0.36	0	NC*				
Female	0.12	0	NC*	Female	1.91	1	NC*

Total	0.49	0	NC*				
Lung and Bronchus				All Sites / Types			
Male	4.51	1	NC*	Male	29.45	17	58 #-
Female	3.64	1	NC*	Female	28.07	20	71
Total	8.15	2	NC*	Total	57.52	37	64 ~-

Obs = observed case count

- + indicates number of observed cases is statistically significantly higher than the expected number of cases
- indicates number of observed cases is statistically significantly lower than the expected number of cases
- # indicates statistical significance at the $p \le 0.05$ level
- ~ indicates statistical significance at the $p \le 0.01$ level, as well as at the $p \le 0.05$ level
- \land indicates statistical significance at the **p** \leq 0.001 level, as well as at the **p** \leq 0.05 and **p** \leq 0.01 levels

^{* =} **SIR** and statistical significance not calculated when **Obs** < 5